Neuropathology and Applied Neurobiology 43, 200-214 Clinicopathologic heterogeneity in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) due to microtubule-associated protein tau (MAPT) p.P301L mutation, including a patient with globular glial tauopathy Aim: The p.P301L mutation in microtubule-associated protein tau (MAPT) is a common cause of frontotemporal dementia and parkinsonism linked to chromosome 17 . We compare clinicopathologic features of five unrelated and three related (brother, sister and cousin) patients with FTDP-17 due to p.P301L mutation. Methods: Genealogical, clinical, neuropathologic and genetic data were reviewed from eight individuals. Results: The series consisted of five men and three women with an average age of death of 58 years (52-65 years) and average disease duration of 9 years (3-14 years). The first symptoms were those of behavioural variant frontotemporal dementia in seven patients and semantic variant of primary progressive aphasia in one. Three patients were homozygous for the MAPT H1 haplotype; five had H1/H2 genotype.
Introduction
Frontotemporal dementia and parkinsonism linked to chromosome is an umbrella term for hereditary tauopathies caused by mutations in the microtubule-associated protein tau gene (MAPT) at chromosome 17q21.3 [1] . Of 16 MAPT exons, alternative splicing of exon 10 results in two functionally distinct isoforms that have either three or four 31-amino acid repeats depending on whether exon 10 is excluded (3R tau) or included (4R tau) [2] . To date more than 50 mutations in exons 1, 9-13 and introns 9 and 10 have been reported in about 200 families (see http:// www.molgen.ua.ac.be/ADMutations) [3] . The p.P301L mutation in exon 10 is one of the most common [3] . The pathogenetic effect of this mutation includes reduced ability of mutated 4R tau to bind to microtubules and promote microtubule assembly [4] , as well as enhanced in vitro heparin-induced assembly into pathological tau filaments [5] .
FTDP-17 follows a pattern of autosomal dominant inheritance with clinical, biochemical and neuropathologic heterogeneity [3] . The phenotypes overlap with phenotypes of sporadic primary tauopathies, including progressive supranuclear palsy [6] , Pick's disease (PiD) [7] , corticobasal degeneration (CBD) [8] and globular glial tauopathy (GGT) [9] .
GGT is a newly recognized 4R tauopathy with extensive white matter tau pathology and characteristic glial inclusions, including Gallyas-positive globular oligodendroglial inclusions (GOI) and globular astrocytic inclusions (GAI). The latter are usually Gallyas-negative or at most show only weak staining with Gallyas silver method [10] . A proposed classification of GGT includes three clinicopathologic subtypes: subtype I with frontotemporal distribution of tau pathology and clinical features of frontotemporal dementia ('FTD-type'); subtype II with pyramidal features from motor cortex involvement and corticospinal tract degeneration ['motor neuron disease (MND)-type']; and subtype III with a combination of FTD and MND ('FTD & MND-type') [10] .
Here, we compare and contrast clinicopathologic features of five unrelated and three related patients with FTDP-17 due to p.P301L mutation, including one patient with a GGT phenotype.
Materials and methods

Subjects and samples
Brains from four unrelated patients with FTDP-17 due to p.P301L mutation were acquired from the brain bank for neurodegenerative disorders at Mayo Clinic in Jacksonville. Brains from the remaining patient and from three individuals of an affected family were acquired from the Department of Laboratory Medicine and Pathology at Mayo Clinic in Rochester. All brains were collected between 2006 and 2012. Autopsies were performed after approval by the next-of-kin. All samples were received after informed consent according to protocols approved by the Mayo Clinic Institutional Review Board.
Genetic, genealogical, clinical and laboratory investigations
Genealogical, clinical and laboratory information was collected by medical chart review. TaqMan â SNP Genotyping Assays were used to determine the MAPT H1/H2 haplotype (rs1052553) and the apolipoprotein E (APOE) genotype (rs429358 and rs7412) following the manufacturer's instructions. Genotype data were analysed on the QuantSudio 7 Flex Real-Time PCR system software (Thermo Fisher Scientific Grand Island, NY, USA).
Tissue sampling and neuropathologic assessment
The brains of Patients 1 and 2 were divided in the midsagittal plane with the right hemibrains fixed in 10% formalin and the left half frozen at À80°C. The left hemisphere was fixed and the right hemisphere was frozen in the remaining six patients. All patients underwent standard methodological procedures for tauopathies. Formalin-fixed tissue was sampled with a standardized dissection and sampling method and embedded in paraffin blocks. The sampled regions included frontal, temporal, parietal, motor, visual and cingulate cortices, amygdala, hippocampus (two levels), nucleus accumbens, lentiform nucleus, thalamus at level of subthalamic nucleus, mesencephalon, pontomesencephalic junction, rostral pons, medulla oblongata and two sections of cerebellum including vermis and deep nuclei. Sections stained with haematoxylin and eosin were used for histological evaluations of neuronal loss and gliosis. Alzheimer-type pathology was assessed with thioflavin-S fluorescent microscopy. Tract degeneration and white matter changes were assessed with Luxol fast blue for myelin and ionizing binding adapter protein 1 immunohistochemistry.
Tau immunohistochemistry (IHC) was performed using a DAKO Autostainer (Universal Staining System, Carpinteria, CA, USA). Sections from paraffin embedded tissue were cut at a thickness of 5 lm and allowed to dry overnight in a 60°oven. Following deparaffinization and rehydration, antigen retrieval was performed by steaming the sections for 30 min in deionized water. For 3R tau and 4R tau antibodies, prior to steaming, tissue sections were incubated for 30 min in 98% formic acid. Endogenous peroxidase was blocked for 5 min with 0.03% hydrogen peroxide. Sections were then treated with 5% normal goat serum for 20 min. Subsequently, sections were incubated for 45 min at room temperature in the following antibodies: mouse monoclonal phospho-tau (CP13-phospho-serine 202; mouse IgG1, 1:1000, gift form Peter Davies, Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health Care System), 3R tau-and 4R tau antibody (RD3, RD4; 1:5000, Millipore, Temecula, CA, USA). After primary antibody incubation, sections were incubated for 30 min at room temperature in EnvisionPlus mouse or rabbit labelled polymer HRP (DAKO Carpinteria, CA, USA). Peroxidase labelling was visualized with the chromogen solution 3,3 0 -diaminobenzidine (DAB-Plus DAKO, Carpinteria, CA, USA). The sections were then counterstained with Lerner 1 haematoxylin (Thermo Fisher Scientific Kalamazoo, MI, USA) and coverslipped with Cytoseal mounting medium (Thermo Fisher Scientific Kalamazoo, MI, USA). In addition, Gallyas silver stain was used to assess argyrophilia of globular inclusions in Patient 1.
Results
Clinical, genealogical, genetic and neuropathologic data of all eight patients are summarized in Tables 1 and 2 . Anatomic distribution and severity of tau pathology is summarized in Table 3 . In all eight patients the MAPT p.P301L (c.902C>T NM_005910) mutation was identified. No deoxyribonucleic acid was available from the relatives of Patients 1-5 to determine segregation pattern of the p.P301L mutation.
Patient 1
Clinical and laboratory findings Patient 1 was a 65-year-old right-handed white woman who at the age of 53 years noticed changes in personality and behaviour consistent with behavioural variant of frontotemporal dementia (bvFTD). This was followed by slow decline in her short-term memory. During the subsequent 4 years, she developed parkinsonian features such as bradykinesia, shuffling gait, symmetric rigidity, stooped posture, intermittent mild rest hand tremor and hypomimia. Initial responsiveness to dopaminergic therapy and fluctuations of cognitive skills led to a tentative diagnosis of dementia with Lewy bodies. Brain magnetic resonance imaging (MRI) revealed moderate ventriculomegaly and fludeoxyglucose (FDG) brain positron emission tomography (PET) scan was normal in the early stage of the disease. As the disease progressed, she exhibited language difficulties, with impaired comprehension and dysnomia but fluent speech, consistent with secondary semantic dysfunction that later evolved to mutism. The family reported episodes of compulsive gambling, urinary incontinence and marked postural instability with backward falls. In the end-stage of the disease, she was wheelchairbound, and she developed bilateral spastic contractures of her distal joints, worse on the left, which were treated with injections of botulinum toxin A to a moderate effect. Trials of dopaminergic (carbidopa/ levodopa), antipsychotic (quetiapine, risperidone) and anti-dementia (rivastigmine) drugs as well as antioxidants (vitamins C, E, coenzyme Q), lorazepam were unsuccessful in the long-term.
The patient's maternal grandmother and mother were clinically diagnosed with early-onset personality changes and dementia. The patient's mother died at 58 years of age. The patient's brother had no history of neurological disease. Genetic studies revealed homozygosity for MAPT H1 haplotype. Her APOE genotype was e3/e3.
Neuropathologic findings
The calculated brain weight was 880 g. There was cortical atrophy of the frontal, temporal and parietal lobes, most marked in the superior frontal gyrus (Figure 1 ). The subjacent cerebral white matter showed tan discoloration and softening. There was moderate enlargement of the lateral ventricles, especially of the frontal horn, and moderate atrophy of the caudate nucleus. The hippocampal formation and amygdala were free of atrophy, but the middle and inferior temporal gyri had Table 1 . Clinical, genealogical and genetic data of eight patients with MAPT p.P301L mutation technetium hexamethylpropylene amine oxime single-photon emission computed tomography; svPPA, semantic variant of primary progressive aphasia; y, years (old).
*Based on leading features at the initial clinical presentation. atrophy ( Figure 1 ). The substantia nigra had decreased pigmentation ( Figure 1 ). Sections from frontal, temporal and parietal lobes, and to a lesser extent from the peri-Rolandic primary cortices, showed neuronal loss and gliosis as well as many ballooned neurons. The white matter was pale, vacuolated, gliotic and depleted of myelinated fibres in a distribution corresponding with the areas with the most severe cortical atrophy. Neither significant neuronal loss nor gliosis were seen in the hippocampus. There was subtle gliosis in the caudate nucleus. The subthalamic nucleus had severe neuronal loss and fibrillary astrogliosis. There was marked neuronal loss with extraneuronal neuromelanin, but no Lewy bodies, in the substantia nigra. No Alzheimer-type changes were appreciated with thioflavin-S fluorescent microscopy.
Tau IHC revealed a range of lesions, including a few grain-like lesions, a few neurofibrillary tangles, more common pretangles, and numerous threads. Glial pathology included sparse coiled bodies (CB) and more numerous GOI and GAI (Figure 2 ), which were strongly positive for 4R tau, but negative for 3R tau. GAI had minimal argyrophilia with Gallyas silver stain, whereas GOI and CB stained positively (Figure 3) . Distribution of GOI included, among other regions, the frontal lobe, motor cortex and corticospinal tract at the level of the lower brainstem. In general, tau pathology was abundant in both grey and white matter.
Summary of clinical and laboratory findings of other p.P301L mutation carriers The seven other p.P301L mutation carriers included five men and two women. All Individuals were white. Patient 2 was of Hispanic ethnicity. Their average age at symptomatic onset was 49 years (42-56), and average disease duration was 8.5 years (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Patients 2-4 were right-handed, and no information was available on the handedness of the Summary of neuropathologic findings of other p.P301L mutation carriers The average calculated whole fixed brain weight was 1036 g (880-1190). Macroscopically, brains of all seven patients showed varying degrees of cortical atrophy of frontal and temporal lobes that in five patients resembled the pattern seen in PiD, with sparing of peri-Rolandic cortices and the posterior part of the superior temporal gyrus (Figure 1 ). All brains showed dilatation of the lateral ventricles and caudate nucleus atrophy. In most cases there was striking atrophy of middle and inferior temporal gyri, which contrasted with a relatively wellpreserved hippocampus and parahippocampal gyrus (Figure 1 ). Except for Patient 4, the substantia nigra had loss of neuromelanin depigmentation (Figure 1 ). The motor cortex was atrophic in Patients 4 and 8.
Microscopically, the hippocampus in Patients 3 and 8 was remarkable for neuronal loss and gliosis in CA1-CA4, with dispersion of dentate fascia neurons; in Patient 4 there was focal dentate fascia neuronal dispersion. Alzheimer-type neurofibrillary pathology was either absent or mild. Patients 2 and 4 had moderate to severe neuronal loss in the subthalamic nucleus. The substantia nigra showed varying degrees of neuronal loss, but no Lewy bodies. Except for Patient 5, tau pathology largely predominated in the cortical grey matter compared with the white matter. Almost all neuronal inclusions resembled pretangles, with only a few well-formed tangles. The lesions were mostly invisible with thioflavin S fluorescent microscopy. Granular fuzzy astrocytes (GFA) were the most frequent form of astrocytic tau pathology. Rare or at most sparse CB were noted in all patients. Patient 2 had astrocytes with proximal granular inclusions with tau IHC, and Patient 5 had lesions that resembles tufted astrocytes. In four patients ballooned neurons were frequent.
Discussion
All eight patients in this study, including five unrelated and three related, were carriers of a c.902C>T mutation (p.P301L) in the MAPT gene, but they had varying clinicopathologic presentations. This is one of the largest series of unrelated autopsied p.P301L carriers published to date. This reflects the fact that our brain bank is a major referral site in North America for neurodegenerative tauopathies [11] . Patient 1 had clinical and neuropathologic features consistent with GGT [10] . This is the first report on GGT caused by the p.P301L mutation. To date 39 sporadic [10, [12] [13] [14] and nine carriers of two exon 11 MAPT mutations (p.K317N (c.951G>C) [9] and p.K317M (c.950A>T) [15] ) have been associated with a GGT phenotype. Of note, until recently GGT was considered a sporadic condition [10] .
Compared to Patient 1 with p.P301L from this study, the p.K317N carrier was also a woman who died at 69 years of age following a shorter disease course of 5 years [9] . The eight family members with p.K317M included five men and three women with a mean age of symptomatic onset of 50 years and a mean disease duration of 6 years [15] . Patient 1 presented initially with bvFTD, whereas behaviour and personality changes were not prominent in p.K317N and p.K317M carriers [9, 15] . Motor neuron disease and parkinsonism were noted in all 10 hereditary patients with GGT [9, 15] . Patient 1 and the p.K317N carrier were homozygous for the H1 MAPT haplotype [9] , whereas no data were available for p.K317M patients [15] . Clinicopathological and genetic findings of the 10 hereditary GGT cases due to MAPT mutations is summarized in Table 4 . Ideomotor apraxia (n = 1/8), loss of verbal fluency (n = 3/8), (Table 4) . Moreover, involvement of superior frontal gyrus and premotor cortex in Patient 1 resembled the atrophy pattern of CBD.
On tau IHC, there was widespread pathology in neurons and glia with GOI and GAI in all 10 hereditary GGT cases [9, 15] (Table 4 ). In Patient 1 and p.K317N carrier, GOI and GAI were immunoreactive for 4R tau, but not 3R tau. GAI in p.K317N were argyrophilic [9] with Gallyas silver staining, whereas GAI in Patient 1 were mostly negative. These results suggest that Patient 1 could be referred to as 'GGT caused by MAPT mutation' rather than 'frontotemporal lobar degeneration with MAPT mutations' [10] . This distinction, however, seems to be largely semantic. Neither the Gallyas method nor IHC were included in the analysis of p.K317M [15] . On the other hand, a subsequent immunohistochemical study showed virtually indistinguishable characteristics of glial lesions in sporadic GGT individuals and p.K317M carriers in terms of a pattern of tau phosphorylation sites, conformation, truncation and ubiquitination [16] . Patients with p.P301L and p.K317N and at least some the eight autopsied p.K317M carriers (see Table 2 and figure 4 in [15] ) were consistent with GGT subtype III (Table 4) [10] .
There were no significant differences between Patient 1 with p.P301L from this study and previously published sporadic patients with GGT, including five patients from the Mayo Clinic brain bank [9, 10, [12] [13] [14] 17] . All sporadic patients with GGT had frontotemporal lobar atrophy with brain weights ranging from 960 to 1300 g [9, 10, [12] [13] [14] 17, 18] . In the five patients from the Mayo series the abundant 4R tau glial pathology had Gallyas-positive GOI. In contrast, GAI were Gallyas-negative in three patients, and either argyrophilic or weakly argyrophilic in two patients [9] . GGT subtype III was found in three patients, whereas two patients had features of subtype I, the most common GGT subtype [9, 10] . Sporadic GGT reported to date have presented with FTD syndromes, predominantly with bvFTD, followed by agrammatic variant of primary progressive aphasia [9, 10, 12, 13, 17, 18] . In one patient, svPPA was diagnosed [14] . The overwhelming majority of sporadic GGT patients were homozygous for the H1 MAPT haplotype [9, 17, 18] .
The clinicopathologic presentations of Patients 2 through 8 in this series were consistent with FTDP-17, but differed from Patient 1 [19] . Brains of Patients 2 through 8 also showed frontotemporal atrophy, but its pattern was more reminiscent of PiD, with sparing of the posterior parts of the superior temporal gyrus (Figure 1) . A similar distribution of atrophy has been reported in a number of reports on p.P301L, notably in family member III-1 from the study of Bird et al. [20] and Family 2 member III:3 from the analysis of van Swieten et al. [21] . In general, p.P301L brains were [15] ; immunohistochemical analysis of p.K317M in a subsequent study: 4R positive globular astro-and oligodendroglial inclusions with a few 3R positive oligodendroglial globular inclusions [16] . §At least some of the eight cases represented GGT subtype III.
thought to show little variation in appearance and severity of atrophy [20] [21] [22] , which manifests early in the disease course. The typical course is 5-10 years and is usually a rapidly progressive process [21] .
Unlike Patient 1, tau pathology in the other patients affected grey matter more than white matter (Figure 2, Table 3 ) and the sparse glial tau pathology had the morphology of CB and GFA rather than of GOI or GAI of Patient 1 ( Table 2) . Two other forms of astrocytic lesions from our series were astrocytes with proximal granular inclusions in Patient 2 and tufted astrocytes in Patient 5. Most descriptions of the neuropathology of p.P301L carriers provide minimal information about glial tau pathology, suggesting that they are not usually a prominent neuropathologic feature. Although 4R tauopathies in general are characterized by both neuronal and glial pathology [21] , it has been suggested that MAPT exon 10 missense mutations, including p.P301L, have less extensive glial pathology than exon 10 splice site mutations [23] . This was observed for all but two (Patients 1 and 5) of the eight patients from this series ( Table 2 and 3) . Glial tau pathology in p.P301L carriers has been described as 'oligodendroglial inclusions,' 'tau-positive glial inclusions', 'glial tangles' or 'tau deposits in glial cells' that were either occasional [21] or abundant [24, 25] . In a few reports more specific terms were used, such as astrocytic plaque-like structures [22, 26, 27] , tuftshaped astrocytes [26] and astrocytes with proximal granular inclusions [16] .
As in previously reported p.P301L carriers [20, 22, [25] [26] [27] [28] , the morphology of neuronal tau pathology in eight patients from this series was predominantly that of pretangles, with diffuse granular cytoplasmic immunoreactivity in a somatodendritic domain (Figure 2 ). In addition, 4R tau cytoplasmic inclusions or aggregates referred to as non-argentophilic Pick-like bodies [25] or argentophilic ubiquitinnegative mini-Pick-like bodies were identified in the dentate gyrus of a few p.P301L carriers [26, 27, 29] . In general, MAPT mutations that affect only 4R tau or are associated with overexpression of 4R tau produce neuronal tau pathology that consists mostly of pretangles. In contrast, Alzheimer-type tangles tend to occur in MAPT mutations that affect all six isoforms [21, 25] . Our study confirms previous observations on frequent occurrence of ballooned neurons in P301L (Table 2) [20, 22, [25] [26] [27] 30] .
In most FTDP-17 cases, the hippocampus and parahippocampal gyrus are relatively spared [25] . In this study all patients except Patient 3 showed either relative or total preservation of the hippocampus that contrasted with more severe atrophy of the middle and inferior temporal gyri (Table 2 ). In the correct circumstance, this feature may be suggestive of p.P301L. This pattern of neocortical atrophy has been noted in a number of previous reports of p. figure 1A in [27] ). Sparing of the hippocampus with prominent or at least moderate involvement of the temporal lobe in general has commonly been reported in p.P301L carriers [20] [21] [22] 24, 28, 30] .
Like in many previous publications on p.P301L, all eight brains from this study had reduced weight (median weight of 1015 g (range = 876-1188 g) vs. 1035 g in 14 patients from hereditary frontotemporal dementia Family I [30] , 915 g in Patient 1, and 1060 g in Patient 2 [22] ). Variable caudate nucleus atrophy and moderate to marked enlargement of the lateral ventricles were observed in all eight patients from this series ( Table 2 ) and in most previously reported p.P301L carriers [21, 22, 25, 28, 30] . Three out of the eight patients from this study had neuronal loss in the subthalamic nucleus, which was severe in two patients. In most p.P301L carriers from the literature, the subthalamic nucleus was only mildly affected [20, 22] . Our series confirmed frequent degeneration of the substantia nigra in FTDP-17 due to p.P301L mutation (Table 2 ) [21] . Despite degeneration, most p.P301L carriers do not have prominent parkinsonian features, at least early in the disease [20, 21, 25, 30, 31] . In our series, parkinsonism was observed only in two patients and gaze palsy was absent. The latter has rarely been seen in p.P301L carriers [25] . The most common clinical presentation in both the present series and published studies was bvFTD (Table 1) [21, 25, 28, 30] . Patient 8 from our study had language impairment and anomia suggestive of svPPA, which in patients with tauopathies is rarely seen, if ever, in PiD, a 3R tauopathy [14] . Except for Patient 1 with GGT, no signs of upper motor dysfunction were documented; however, motor cortex atrophy or corticospinal tract degeneration was also observed in Patients 3, 4 and 8. Pyramidal signs have rarely been noted in p.P301L carriers and mainly in the late stage of the disease [30] .
Patients 3 and 8 from this series had generalized seizures and both had pathologic features of hippocampal sclerosis with dentate fascia neuronal dispersion. Of note, epileptic seizures are rare in FTDP-17, but have been reported in carriers of another MAPT codon 301 mutation, p.P301S [32] .
Our study confirms previous observations on intraand inter-familial phenotypic heterogeneity of p.P301L carriers, but its explanation is largely unknown [31] . It is likely that environmental or genetic factors other than the mutation play a role in the phenotypic diversity. Disease duration may be a contributing factor. Individuals with p.P301L mutation and longer disease durations seem to have more severe clinicopathologic findings [25] . Other factors to consider are MAPT and APOE haplotypes as well as race. Of the two major MAPT haplotypes, H2 occurs in Caucasian populations with allele frequencies of 20%-30% and <5% in Asian populations [33] . All eight patients from this study were white, as are the majority of previously reported p.P301L carriers [30] . Previous reports showed that p.P301L may be more frequent on the H2 haplotype [33] ; however, there are a number of reported patients with H1 haplotype [29, 31, 33] . In our series, the H1/ H2 genotype was identified in five p.P301L carriers, whereas three individuals were homozygous for H1 haplotype (Table 1) . Previous suggestions that H1 is associated with parkinsonism and H2 with dementia in p.P301L carriers [33] could not be confirmed either in our series or in Asian patients with p.P301L and H1 haplotype who had dementia as the most common phenotype [28, 31, 34] . The APOE e4 allele is considered a genetic risk factor for Alzheimer-type pathology and reducing the average age of onset [35, 36] . This observation could not be confirmed either by Bird et al. [20] or Patient 3 from our series.
In conclusion, the major finding of this study is that MAPT p.P301L mutation is associated with clinical and pathologic heterogeneity, including a GGT phenotype that is indistinguishable from sporadic GGT. This finding confirms previous observations that GGT is not always a sporadic condition, but can be caused by MAPT mutations. Sparing of the hippocampus with severe involvement of adjacent inferior and middle temporal gyri is the most striking macroscopic finding suggestive of p.P301L mutation. The p.P301L mutation may lead to different clinicopathologic phenotypes in both unrelated and related carriers. It is likely that some environmental and genetic factors other than the mutation itself play a role in the phenotypic heterogeneity of the p.P301L carriers.
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